Rheumatology, Spondyloarthropathies
10. Feb 2016
CRP and a biomarker of type I collagen degradation, C1M, can differentiate anti-inflammatory treatment response in ankylosing spondylitis
AIM:
To investigate if tissue turnover biomarkers were efficacy biomarkers in ankylosing spondylitis and if the biomarkers at baseline predicted a good outcome (BASDAI50).
PATIENTS & METHODS:
Twenty-two etanercept treated ankylosing spondylitis patients were investigated for inflammation (CRP, …
Read the publication
Journal:
Authors:
- Siebuhr AS,
- Bay-Jensen AC,
- Karsdal MA,
- Lories RJ,
- de Vlam K,
Rheumatology, Osteoarthritis
1. Aug 2014
Biomarkers of cartilage and surrounding joint tissue
The identification and clinical demonstration of efficacy and safety of osteo- and chondro-protective drugs are met with certain difficulties. During the last few decades, the pharmaceutical industry has, in the field of rheumatology, experienced disappointments associated with the development of di…
Read the publication
Journal:
Authors:
- Siebuhr AS,
- He Y,
- Gudmann NS,
- Gram A,
- Kjelgaard-Petersen CF,
- Qvist P,
- Karsdal MA,
- Bay-Jensen AC,